Human Cytolytic Fusion Proteins: Modified Versions of Human Granzyme B and Angiogenin Have the Potential to Replace Bacterial Toxins in Targeted Therapies against CD64+ Diseases

Human Cytolytic Fusion Proteins: Modified Versions of Human Granzyme B and Angiogenin Have the Potential to Replace Bacterial Toxins in Targeted Therapies against CD64+ Diseases

Targeted therapies for the treatment of cancer, but also inflammation and autoimmune diseases will reduce major side effects accompanied with conventional treatment modalities. The immunotoxin concept uses bacterial or plant toxins, coupled to antibodies or natural ligands targeting cancer cells. In...

Full description

Bibliographic Details
Main Authors: Nina Berges, Grit Hehmann-Titt, Dmitrij Hristodorov, Georg Melmer, Theo Thepen, Stefan Barth
Format: Article
Language:English
Published: MDPI AG 2014-02-01
Series:Antibodies
Subjects:
immunotherapy
immunotoxin
humanization
CD64
granzyme B
angiogenin
endosomal release
Online Access:http://www.mdpi.com/2073-4468/3/1/92

Internet

http://www.mdpi.com/2073-4468/3/1/92

Similar Items